完成新冠疫苗基础免疫系列接种的≥18岁人群中重症新冠结局的危险因素——美国465家医疗机构,2020年12月至2021年10月
该研究利用美国大型医疗数据库465家机构的数据,评估完成基础免疫(2剂mRNA疫苗或1剂JNJ-78436735,且发病前≥14天)后发生重症新冠的频率与危险因素。2020年12月至2021年10月共1,228,664人完成基础免疫,其中2,246人(每1万接种者18.0例)发生新冠,189人(每1万接种者1.5例)出现重症结局,36人死亡(每1万接种者0.3例死亡)。≥65岁、免疫抑制或患有其他六种基础疾病之一者重症风险更高,所有重症者至少有一项上述危险因素。
要点
- 完成基础免疫后重症新冠结局罕见:每1万接种者1.5例,死亡每1万接种者0.3例
- ≥65岁、免疫抑制或患其他基础疾病者重症风险更高
- 全部重症者至少有一项危险因素,死亡者中77.8%有四项及以上危险因素
核心结论
- 完成基础免疫后重症新冠结局罕见,但≥65岁、免疫抑制或患有其他基础疾病者风险可能升高。
- 这些人群应接受针对性干预,包括慢病管理、减少暴露的防护措施、额外基础剂次和加强剂次疫苗以及有指征的有效药物治疗,以降低重症新冠结局风险。
- 提高新冠疫苗接种覆盖率是公共卫生优先事项。
研究设计与样本
- 利用美国大型医疗数据库465家机构的数据,评估完成基础免疫后发生重症新冠结局的频率与危险因素。
- 基础免疫定义为发病前≥14天接种2剂mRNA疫苗(BNT162b2或mRNA-1273)或1剂JNJ-78436735。
- 重症新冠结局定义为因急性呼吸衰竭诊断住院、需要无创通气、入住重症监护病房(包括所有需要有创机械通气者)或死亡(包括出院转临终关怀)。
主要发现
- 2020年12月至2021年10月共1,228,664人完成基础免疫,其中2,246人发生新冠,为每1万接种者18.0例。
- 189人出现重症结局,为每1万接种者1.5例,其中36人死亡,为每1万接种者0.3例死亡。
- ≥65岁、免疫抑制或患有其他六种基础疾病之一者重症结局风险更高。
- 所有重症结局者均至少有一项上述危险因素,死亡者中77.8%有四项及以上危险因素。
关键数值与推荐
- 基础免疫:发病前≥14天接种2剂mRNA疫苗(BNT162b2或mRNA-1273)或1剂JNJ-78436735。
- 重症结局:因急性呼吸衰竭诊断住院、需要无创通气、入住重症监护病房(包括所有需要有创机械通气者)或死亡(包括出院转临终关怀)。
- 高危因素包括≥65岁、免疫抑制以及六种其他基础疾病中的至少一种。
临床怎么用
- 作者建议,≥65岁、免疫抑制或患有其他基础疾病者应接受针对性干预,包括慢病管理、减少暴露的防护措施、额外基础剂次和加强剂次疫苗以及有指征的有效药物治疗。
- 作者认为提高新冠疫苗接种覆盖率是公共卫生优先事项。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination against SARS-CoV-2, the virus that causes COVID-19, is highly effective at preventing COVID-19-associated hospitalization and death; however, some vaccinated persons might develop COVID-19 with severe outcomes† (1,2). Using data from 465 facilities in a large U.S. health care database, this study assessed the frequency of and risk factors for developing a severe COVID-19 outcome after completing a primary COVID-19 vaccination series (primary vaccination), defined as receipt of 2 doses of an mRNA vaccine (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) or a single dose of JNJ-78436735 [Janssen (Johnson & Johnson)] ≥14 days before illness onset. Severe COVID-19 outcomes were defined as hospitalization with a diagnosis of acute respiratory failure, need for noninvasive ventilation (NIV), admission to an intensive care unit (ICU) including all persons requiring invasive mechanical ventilation, or death (including discharge to hospice). Among 1,228,664 persons who completed primary vaccination during December 2020-October 2021, a total of 2,246 (18.0 per 10,000 vaccinated persons) developed COVID-19 and 189 (1.5 per 10,000) had a severe outcome, including 36 who died (0.3 deaths per 10,000). Risk for severe outcomes was higher among persons who were aged ≥65 years, were immunosuppressed, or had at least one of six other underlying conditions. All persons with severe outcomes had at least one of these risk factors, and 77.8% of those who died had four or more risk factors. Severe COVID-19 outcomes after primary vaccination are rare; however, vaccinated persons who are aged ≥65 years, are immunosuppressed, or have other underlying conditions might be at increased risk. These persons should receive targeted interventions including chronic disease management, precautions to reduce exposure, additional primary and booster vaccine doses, and effective pharmaceutical therapy as indicated to reduce risk for severe COVID-19 outcomes. Increasing COVID-19 vaccination coverage is a public health priority.
引用
- Yek C, Warner S, Wiltz JL, et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 34990440. doi:10.15585/mmwr.mm7101a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。